A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies

Exclusion Criteria

• •1. Symptomatic (secondary) parkinsonism (ie. drug induced)
• •2. Atypical parkinsonian variants
• •3. History of cancer (except basal or squamous cell skin cancer) within 5 years
• •4. Known liver disease
• •5. Hematological disorders
• •6. History of stereotactic or ablative brain surgery
• •7. Treatment with an investigational drug or device within the last 30 days
• •8. Pregnancy
• •9. Inability to comply with or tolerate study procedures
• •10. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000)
• •MSA Subjects:
• •1. Symptomatic (secondary) parkinsonism (ie. drug induced)
• •2. History of cancer (except basal or squamous cell skin cancer) within 5 years
• •3. Known liver disease
• •4. Hematological disorders
• •5. History of stereotactic or ablative brain surgery
• •6. Treatment with an investigational drug or device within the last 30 days
• •7. Pregnancy
• •8. Inability to comply with or tolerate study procedures
• •9. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000)
• •For RBD Subjects:
• •1. Signs for symptoms suggestive of parkinsonian disorder
• •2. History of cancer (except basal or squamous cell skin cancer) within 5 years
• •3. Known liver disease
• •4. Hematological disorders
• •5. History of stereotactic or ablative brain surgery
• •6. Treatment with an investigational drug or device within the last 30 days
• •7. Pregnancy
• •8. Inability to comply with or tolerate study procedures
• •9. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000)
• •For NPH:
• •1. History of cancer (except basal or squamous cell skin cancer) within 5 years
• •2. Known liver disease
• •3. Hematological disorders
• •4. History of stereotactic or ablative brain surgery
• •5. Treatment with an investigational drug or device within the last 30 days
• •6. Pregnancy
• •7. Inability to comply with or tolerate study procedures
• •8. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000)
• •For Controls:
• •1. Signs or symptoms suggestive of parkinsonian disorder
• •2. History of rapid eye movement (REM) Sleep Behavior Disorder (RBD)
• •3. History of cancer (except basal or squamous cell skin cancer) within 5 years
• •4. Known liver disease
• •5. Hematological disorders
• •6. History of stereotactic or ablative brain surgery
• •7. Treatment with an investigational drug or device within the last 30 days
• •8. Pregnancy
• •9. Inability to comply with or tolerate study procedures
• •10. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000)